COMPASS THERAPEUTICS INC (CMPX) Stock News
NASDAQ:CMPX - Nasdaq - US20454B1044 - Common Stock
CMPX Latest News and Analysis
These stocks have an unusual volume in today's session
In today's session, these stocks are experiencing unusual volume.
Let's take a look at the stocks that are in motion in today's session.
What's going on in today's session
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
Compass Therapeutics to Participate in Upcoming Investor Events
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data...
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients...
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
Compass Therapeutics to Participate in Upcoming Investor Events
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
CMPX Stock Earnings: Compass Therapeutics Meets EPS for Q2 2024
CMPX stock results show that Compass Therapeutics met analyst estimates for earnings per share the second quarter of 2024.
CMPX Stock Earnings: Compass Therapeutics Meets EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Compass Therapeutics (NASDAQ:CMPX) just reported results for the second quarter...
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
Compass Therapeutics announces 2nd quarter results and provides clinical results update...
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
Compass Therapeutics Announces CEO Transition
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human...
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
CMPX Stock Earnings: Compass Therapeutics Beats EPS for Q1 2024
CMPX stock results show that Compass Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or...
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers,...
3 Penny Stocks With the Power to 10X Your $1K Investment
The 10X penny stocks discussed here are a much more reliable investment than many other alternatives investors are likely to encounter.
CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023
CMPX stock results show that Compass Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Compass Therapeutics (NASDAQ:CMPX) just reported results for the fourth quarter...
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update...
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
Compass Therapeutics provides updates regarding ongoing projects (NASDAQ:CMPX)
Compass Therapeutics, an oncology-focused biopharmaceutical company, provides updates on its operations, including timelines for clinical studies and its...
Compass Therapeutics Provides Corporate Update
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in...
Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Opened 29 clinical sites and continue to enroll patients in COMPANION-002, a U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel in patients...
3 Healthcare Stocks To Make You The Millionaire Next Door: October Edition
These are the healthcare stocks to buy as they represent companies investing in research and development for growth and value creation.
Compass Therapeutics to Participate in Upcoming Investor Events
BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...